Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase III follow-up of mannan-conjugated birch pollen allergoid (T502) after T502-045
2022-004082-20Phase 3Completed
- Sponsor
- Inmunotek
- Start
- Jan 2023
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of birch pollen allergen extract in allergic rhinoconjunctivitis (ARC), sponsored by Inmunotek. Started Jan 2023; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2022-004082-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004082-20.